PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus

Journal of Nuclear Medicine

Volumn 45, Issue 1, 2004, Pages 56-68

  Kostakoglu, Lale ^a,b   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

18F FDG PET; Esophageal carcinoma; Head and neck carcinoma; Oncology; PET; PET CT; Response to therapy

Indexed keywords

ANTIINFECTIVE AGENT; FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER CHEMOTHERAPY; ESOPHAGUS CARCINOMA; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; CARCINOMA; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS TUMOR; HEAD AND NECK TUMOR; METHODOLOGY; PROGNOSIS; RADIOTHERAPY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 1842556156     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Boice J, Land C, Preston D. Ionizing radiation. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press; 1996:319-354.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1997;47:5-27.
3. Scantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx. In: Devita VT, Helmann S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997:741-801.
4. Al-Sarraf M. Head and neck cancer: present status and future prospects of adjuvant chemotherapy. Cancer Invest. 1995;13:41-53.
5. Manam R, Al-Sarraf M. Head and neck cancer. In: Giaccone G, Schilsky R, Sondel P, eds. Cancer Chemotherapy and Biological Response Modifiers. Annual 20. Amsterdam, The Netherlands: Elsevier Science BV; 2002:1-16.
6. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol. 2000;12:229-239.
7. Berlangieri SU, Brizel DM, Sher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck. 1994;16:340-346.
8. Greven KM, Williams DW, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355-1359.
9. McGuirt WF, Greven K, Williams D, et al. FDG PET scanning in head and neck oncology: a review. Head Neck. 1998;20:208-215.
10. Sakamato H, Nakai Y, Ohashi Y, et al. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose FDG PET of head and neck squamous cell carcinomas. Acta Otolaryngol. 1998;538(suppl):254-260.
11. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651-658.
12. Dalsaso TA, Lowe VJ, Dunphy FR, Martin DS, Boyd JH, Stack BC. FDG PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging. 2000;3:1-5.
13. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck. 1997;19:666-674.
14. Collins BT, Gardner LJ, Verma AK, Lowe VJ, Dunphy FR, Boyd JH. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol. 1998;42:1325-1329.
15. Brun E, Ohlsson T, Erlandsson K, et al. Early prediction of treatment outcome in head and neck cancer with 2-18FDG FDG PET. Acta Oncol. 1997;36:741-747.
16. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
17. 18F-FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med. 1999;40:1132-1137.
18. 18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-1404.
19. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, Seifert E, Strauss LG. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg. 1995;121:272-276.
20. 3H]thymidine, and gallium-67. J Nucl Med. 1991;32:2118-2123.
21. Ojiri H, Mancuso AA, Mendenhall WM, Stringer SP. Lymph nodes of patients with regional metastases from head and neck squamous cell carcinoma as a predictor of pathologic outcome: size changes at CT before and after radiation therapy. AJNR. 2002;23:1627-1631.
22. Perie S, Montravers F, Kerrou K, et al. Fluorodeoxyglucose imaging using a coincidence gamma camera to detect head and neck squamous cell carcinoma and response to chemotherapy. Ann Otol Rhinol Laryngol. 2002;111:763-771.
23. Kitagawa Y, Sano K, Nishizawa S, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging. 2003;30:63-71.
24. Zimny M, Kaiser HJ, Cremerius U, et al. F-18-FDG positron imaging in oncological patients: gamma camera coincidence detection versus dedicated PET. Nuklearmedizin. 1999;38:108-114.
25. Conessa C, Clement P, Foehrenbach H, et al. Value of positron-emission tomography in the post-treatment follow-up of epidermoid carcinoma of the head and neck. Rev Laryngol Otol Rhinol. 2001;122:253-258.
26. Goerres GW, Mosna-Firlejczyk K, Steurer J, von Schulthess GK, Bachmann LM. Assessment of clinical utility of (18)F-FDG PET in patients with head and neck cancer: a probability analysis. Eur J Nucl Med Mol Imaging. 2003;30:562-571.
27. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol. 2001;19:2504-2508.
28. Rege S, Safa AA, Chaiken L, Hoh C, Juillard G, Withers HR. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol. 2000;23:164-169.
29. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85-92.
30. 18F]FDG PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol. 2003;39:170-177.
31. 18F-FDG) in head and neck cancer. J Laryngol Otol. 1999;113:548-554.
32. Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion - report of six cases. Radiology. 2002;224:153-156.
33. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:535-542.
34. Koh W-J, Rasey JS, Evans ML. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
35. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171-1182.
36. 11C]methionine-positron emission tomography. Radiother Oncol. 1999;52:225-232.
37. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
38. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77:845-857.
39. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88:338-356.
40. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997;114:210-217.
41. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000;120:1085-1092.
42. Hickey K, Grehan D, Reid IM, et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer. 1994;74:1693-1698.
43. Kitamura K, Saeki H, Kawaguchi H, et al. Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology. 2000;47:419-423.
44. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg. 1995;221:677-683.
45. Sauter ER, Coia LR, Eisenberg BL, Hanks GE. Transforming growth factor alpha expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:567-569.
46. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg. 1998;85:1403-1406.
47. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
48. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368.
49. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron tomography. Ann Surg. 2001;233:300-309.
50. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response to neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184:279-283.
51. Nakamura R, Obara T, Katsuragawa S. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after RT. Radiat Med. 2002;20:181-186.
52. 18FDG PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432.
53. Wolfe WG, Vaughn AL, Seigler HF, et al. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg. 1993;105:749-755.
54. Kobori O, Kirihara Y, Kosaka N, Hara T. Positron emission tomography of oesophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer. 1999;86:1638-1648.
55. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765-769.
56. Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG PET for staging of oesophageal cancer? Eur J Nucl Med. 2001;28:1845-1849.
57. Wahl RL, Towsend DW, Meltzer CC, Von Schulthess GK, Fishman EK. CT/PET fusion imaging [abstract]. Radiology. 2002;225:42.
58. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med. 2002;29:1393-1398.